InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,399.22
(
-0.51%
)
US TECH 100
18,362.00
(
-0.93%
)
Dow Jones
39,935.07
(
0.20%
)
Brent Oil
81.74
(
0.25%
)
Bitcoin
67,343.18
(
2.36%
)
Post# of 43137
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

cowtown jay

Send PM Follow Ignore
Followers 87
Posts 6765
Boards Moderated 1
Alias Born 09/18/2009

cowtown jay

Re: None

Friday, 12/29/2023 11:13:25 AM

Friday, December 29, 2023 11:13:25 AM

Post# of 43137
Chapter 2 The ancillary benefits

In our first quarter 10-Q, the company described current trials of lenzilumab that were all sponsored by partners. The trials focused on CMML, aGvHD, and CAR-T.

In each indication, lenzilumab promises to have demonstrated game-changing improvement, which could lead to long-delayed Regulatory authorizations or approvals. Shareholders and patients will welcome these authorizations and approvals to get lenz into the market. This was, after all, the primary focus of management, prior to 2020.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up